Saturday 17 October 2026
Export ANAB’s income statement to Excel — free account
AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
46.61
2.10
−4.31%
Follow ANAB
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
5 | 3 | 4 | 2 | 3 | 5 | 3 | 4 | 3 | 2 |
Altman Z-Score |
0.84 | (1.47) | (1.45) | 0.19 | 1.44 | 12.03 | 5.20 | 27.96 | 36.84 | — |
P/S ratio |
3.96 | 2.75 | 22.71 | 53.33 | 10.06 | 4.71 | 18.32 | 59.07 | 83.01 | 1.79 |
P/FCF ratio |
47.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.30) | (1.29) | (1.26) | 1.64 | 4.57 | 24.50 | 15.85 | 26.06 | 18.15 | 4.13 |
P/Operating CF |
9.48 | (3.76) | (11.34) | (51.35) | (25.12) | 10.41 | (18.54) | (85.38) | (275.76) | (5.36) |
Beneish M-Score |
(2.34) | 1.51 | (1.09) | 3.11 | — | — | — | (4.21) | (2.33) | 1.11 |
P/B ratio |
24.98 | 3.54 | 4.42 | 2.09 | 1.78 | 0.99 | 0.72 | 2.16 | 4.31 | 0.00 |
Price to Tangible BV |
24.98 | 3.54 | 4.42 | 2.09 | 1.78 | 0.99 | 0.72 | 2.16 | 4.31 | 0.00 |
EV/Sales |
2.64 | (1.45) | 0.06 | 10.68 | 1.42 | 0.00 | (4.92) | 35.16 | 67.94 | (0.45) |
EV/EBITDA |
13.61 | 1.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.72 | 0.00 | 0.00 | 2.69 |
EV/Operating CF |
31.49 | 0.98 | (0.01) | (1.49) | (1.96) | 0.00 | 1.13 | (12.88) | (55.85) | 0.84 |
EV/FCF |
31.63 | 0.98 | (0.01) | (1.49) | (1.90) | 0.00 | 1.12 | (12.60) | (55.02) | 0.83 |
Quick Ratio |
8.94 | 9.38 | 10.62 | 16.99 | 34.10 | 19.86 | 12.67 | 19.57 | 17.74 | 9.91 |
Current Ratio |
9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 | 12.79 | 19.89 | 17.93 | 10.20 |
Net Debt/EBITDA |
(6.84) | 3.14 | 2.27 | 3.83 | 10.11 | 18.06 | 3.44 | 6.31 | 8.42 | 13.40 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.29% | 22.21% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.35 |
Asset Turnover |
0.55 | 0.20 | 0.03 | 0.02 | 0.12 | 0.18 | 0.02 | 0.01 | 0.05 | 0.28 |
Operating CF/Net income |
(1.49) | 0.93 | 0.74 | 0.57 | 0.79 | 0.71 | 0.71 | 0.79 | 0.65 | 2.12 |
Capex/Depreciation |
0.04 | 0.05 | 0.10 | 2.08 | (0.52) | (0.27) | 0.66 | 1.16 | (1.58) | (0.21) |
Interest Coverage |
0.60 | (2.29) | (9.09) | (15.25) | (131.82) | (6.03) | (103.20) | (40.39) | (16.21) | (6.60) |
| (24.49%) | (182.71%) | (93.44%) | (41.62%) | (15.35%) | (4.97%) | (21.84%) | (15.53%) | (22.33%) | 11.60% | |
| (3.12%) | (31.02%) | (30.79%) | (20.54%) | (10.91%) | (4.68%) | (20.62%) | (14.71%) | (15.36%) | (7.19%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (484.87%) | (218.14%) | (70.34%) | (26.96%) | (102.47%) |
Return on Tangible Assets |
(4.23%) | (37.40%) | (44.04%) | (30.41%) | (10.70%) | (5.27%) | (27.82%) | (14.90%) | (12.57%) | (8.04%) |
Average Days of Receivables |
52.66 | 163.01 | 145.75 | 50.35 | 5.06 | 0.00 | 0.00 | 12.70 | 58.44 | 116.89 |
Research and Development Expense of Revenue |
57.96% | 179.49% | 771.01% | 863.21% | 155.91% | 106.70% | 1,241.73% | 1,123.92% | 294.43% | 92.42% |
Selling, General and Administrative Expense of Revenue |
21.63% | 46.44% | 244.48% | 356.21% | 34.02% | 25.14% | 201.18% | 310.52% | 93.38% | 25.71% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
15.38% | 37.30% | 193.54% | 265.93% | 24.29% | 15.33% | 155.14% | 199.22% | 43.78% | 6.95% |
Graham Net Nets |
0.02 | 0.08 | 0.11 | 0.18 | 0.42 | 0.96 | 1.19 | 0.39 | 0.17 | 1.18 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.96 |
Earnings Yield |
(0.90%) | (59.00%) | (42.02%) | (23.46%) | (9.04%) | (5.09%) | (33.33%) | (5.88%) | (2.43%) | (14.26%) |
Free Cash Flow Yield |
2.11% | (54.15%) | (31.21%) | (13.48%) | (7.44%) | (3.76%) | (24.00%) | (4.72%) | (1.49%) | (30.39%) |
Revenue per Share |
8.16 | 3.22 | 0.64 | 0.37 | 2.30 | 2.75 | 0.30 | 0.20 | 0.51 | 6.33 |
Operating CF per Share |
0.68 | (4.77) | (4.49) | (2.61) | (1.67) | (0.52) | (2.57) | (1.97) | (0.98) | (3.42) |
Capex per Share |
0.00 | (0.01) | (0.03) | (0.01) | (0.05) | (0.02) | (0.03) | (0.04) | (0.01) | (0.02) |
Free Cash Flow per Share |
0.68 | (4.78) | (4.52) | (2.63) | (1.72) | (0.54) | (2.60) | (2.01) | (1.00) | (3.44) |
Cash per Share |
10.84 | 13.58 | 14.52 | 15.67 | 19.98 | 14.42 | 13.83 | 17.31 | 12.56 | 19.43 |
Shareholders Equity per Share |
1.29 | 2.50 | 3.27 | 9.31 | 12.99 | 14.53 | 14.97 | 19.71 | 15.55 | 14.89 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.29 | 2.50 | 3.27 | 9.31 | 12.99 | 14.53 | 14.97 | 19.71 | 15.55 | 14.89 |
Free Cash Flow |
19.61 | (135.69) | (121.61) | (73.95) | (47.27) | (14.73) | (70.32) | (49.57) | (19.73) | (9.08) |
Working Capital |
311.63 | 386.45 | 369.39 | 421.15 | 537.78 | 376.74 | 348.20 | 412.38 | 238.61 | 52.50 |
Capital Expenditures |
(0.09) | (0.36) | (0.81) | (0.36) | (1.35) | (0.57) | (0.80) | (1.06) | (0.29) | (0.05) |
Net Current Asset Value |
23.07 | 18.91 | 42.55 | 98.93 | 267.23 | 376.74 | 347.54 | 411.58 | 230.91 | 35.30 |
EV/EBIT |
12.95 | 1.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 0.00 | 0.00 | 2.48 |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.03 | 0.02 | 0.01 | 0.10 | 0.21 | 0.03 | 0.00 |
Price to Operating Income |
19.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(1.69) | (4.28) | (3.88) | (0.08) | 1.13 | 1.17 | (0.76) | (0.64) | 0.28 | 0.49 |
Cash ROIC |
5.62% | (29.74%) | (25.39%) | (10.51%) | (5.23%) | (1.86%) | (9.02%) | (5.43%) | (3.50%) | (8.70%) |
Accounts Receivable Turnover |
6.29 | 3.83 | 4.15 | 8.96 | 120.33 | 0.00 | 0.00 | 5.63 | 2.88 | 5.08 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | — | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | — | — | — | 0.00 | 0.00 |
Average Receivables |
37.31 | 23.81 | 4.14 | 1.15 | 0.53 | — | — | 0.89 | 3.47 | 3.28 |
Average Payables |
3.94 | 4.35 | 3.74 | 2.26 | 2.98 | 10.23 | 10.84 | 3.88 | 2.30 | 1.90 |
Average Assets |
424.11 | 468.11 | 531.39 | 626.73 | 529.81 | 425.87 | 472.10 | 419.18 | 195.77 | 59.23 |
Average Common Equity |
54.04 | 79.49 | 175.10 | 309.27 | 376.58 | 400.87 | 445.69 | 396.97 | 134.67 | (36.71) |
Columns are period end dates